Item request has been placed!
×
Item request cannot be made.
×
Processing Request
A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE
- Publication Information:
Original Publication: San Francisco, CA : Public Library of Science
- Subject Terms:
- Abstract:
Background: Visceral leishmaniasis is a neglected parasitic disease with no vaccine available and its pharmacological treatment is reduced to a limited number of unsafe drugs. The scarce readiness of new antileishmanial drugs is even more alarming when relapses appear or the occurrence of hard-to-treat resistant strains is detected. In addition, there is a gap between the initial and late stages of drug development, which greatly delays the selection of leads for subsequent studies.
Methodology/principal Findings: In order to address these issues, we have generated a red-shifted luminescent Leishmania infantum strain that enables long-term monitoring of parasite burden in individual animals with an in vivo limit of detection of 106 intracellular amastigotes 48 h postinfection. For this purpose, we have injected intravenously different infective doses (104-5x108) of metacyclic parasites in susceptible mouse models and the disease was monitored from initial times to 21 weeks postinfection. The emission of light from the target organs demonstrated the sequential parasite colonization of liver, spleen and bone marrow. When miltefosine was used as proof-of-concept, spleen weight parasite burden and bioluminescence values decreased significantly.
Conclusions: In vivo bioimaging using a red-shifted modified Leishmania infantum strain allows the appraisal of acute and chronic stage of infection, being a powerful tool for accelerating drug development against visceral leishmaniasis during both stages and helping to bridge the gap between early discovery process and subsequent drug development.
Competing Interests: The authors have declared that no competing interests exist.
- References:
J Immunol. 2001 Feb 1;166(3):1912-20. (PMID: 11160239)
Antimicrob Agents Chemother. 2001 Jun;45(6):1872-5. (PMID: 11353640)
Clin Diagn Lab Immunol. 2001 Jul;8(4):828-31. (PMID: 11427436)
Am J Pathol. 2002 Aug;161(2):429-37. (PMID: 12163368)
Nat Immunol. 2002 Dec;3(12):1185-91. (PMID: 12436111)
Antimicrob Agents Chemother. 1992 Aug;36(8):1630-4. (PMID: 1329624)
Immunol Rev. 2004 Oct;201:239-53. (PMID: 15361245)
Parasite Immunol. 2006 May;28(5):173-83. (PMID: 16629702)
Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S17-20. (PMID: 16730362)
Science. 2009 May 8;324(5928):804-7. (PMID: 19423828)
PLoS Pathog. 2009 May;5(5):e1000431. (PMID: 19436710)
Trends Parasitol. 2009 Oct;25(10):464-73. (PMID: 19734094)
Anal Biochem. 2010 Jan 15;396(2):290-7. (PMID: 19748472)
Lancet. 2011 Feb 5;377(9764):443-4. (PMID: 21255829)
Indian J Med Res. 2011 Jan;133:27-39. (PMID: 21321417)
World Health Organ Tech Rep Ser. 2010;(949):xii-xiii, 1-186, back cover. (PMID: 21485694)
Cell Microbiol. 2011 Jul;13(7):978-91. (PMID: 21501362)
Nat Biotechnol. 2011 Jul 17;29(8):757-61. (PMID: 21765402)
PLoS Negl Trop Dis. 2011 Sep;5(9):e1323. (PMID: 21931877)
PLoS Negl Trop Dis. 2012 Jan;6(1):e1469. (PMID: 22292094)
Clin Infect Dis. 2012 Aug;55(4):543-50. (PMID: 22573856)
PLoS One. 2012;7(5):e35671. (PMID: 22693548)
PLoS Negl Trop Dis. 2012;6(6):e1674. (PMID: 22724029)
J Antimicrob Chemother. 2012 Nov;67(11):2707-12. (PMID: 22782488)
Trends Parasitol. 2012 Sep;28(9):377-84. (PMID: 22832368)
Clin Infect Dis. 2013 Jun;56(11):1530-8. (PMID: 23425958)
QJM. 2014 Jan;107(1):7-14. (PMID: 23744570)
J Infect Dis. 2014 Jan 15;209(2):290-9. (PMID: 23922369)
J Immunol. 2013 Dec 1;191(11):5542-50. (PMID: 24154626)
PLoS Negl Trop Dis. 2013 Nov 21;7(11):e2571. (PMID: 24278497)
PLoS Negl Trop Dis. 2014 Jan 02;8(1):e2603. (PMID: 24392168)
Cell Microbiol. 2014 Sep;16(9):1285-300. (PMID: 24712539)
Clin Epidemiol. 2014 May 03;6:147-54. (PMID: 24833919)
PLoS Negl Trop Dis. 2014 Aug 07;8(8):e3053. (PMID: 25101665)
J Infect. 2014 Nov;69 Suppl 1:S10-8. (PMID: 25238669)
Drug Discov Today. 2015 Jan;20(1):114-21. (PMID: 25256779)
Expert Opin Pharmacother. 2015 Feb;16(2):237-52. (PMID: 25346016)
Int J Parasitol Drugs Drug Resist. 2014 May 22;4(3):355-7. (PMID: 25516847)
Curr Protoc Immunol. 2015 Feb 02;108:19.2.1-24. (PMID: 25640990)
PLoS Negl Trop Dis. 2015 Feb 13;9(2):e0003556. (PMID: 25679212)
PLoS Pathog. 2015 Feb 25;11(2):e1004683. (PMID: 25714830)
PLoS Negl Trop Dis. 2015 Mar 31;9(3):e0003666. (PMID: 25826250)
PLoS Negl Trop Dis. 2015 Sep 03;9(9):e0003889. (PMID: 26334763)
Semin Immunopathol. 2016 Mar;38(2):249-60. (PMID: 26678994)
PLoS Negl Trop Dis. 2016 Sep 14;10(9):e0004880. (PMID: 27627654)
Parasitol Int. 2017 Feb;66(1):933-939. (PMID: 27794505)
Antimicrob Agents Chemother. 2017 Aug 24;61(9):. (PMID: 28630200)
PLoS Negl Trop Dis. 2017 Sep 25;11(9):e0005924. (PMID: 28945751)
PLoS Negl Trop Dis. 2017 Dec 14;11(12):e0006052. (PMID: 29240765)
Lipids. 1987 Nov;22(11):925-6. (PMID: 3444386)
Parasite Immunol. 1985 Sep;7(5):545-55. (PMID: 3877902)
J Immunol. 1997 Apr 15;158(8):3813-21. (PMID: 9103448)
Antimicrob Agents Chemother. 1998 Oct;42(10):2722-5. (PMID: 9756784)
- Accession Number:
0 (Antiprotozoal Agents)
0 (Luminescent Proteins)
107-73-3 (Phosphorylcholine)
53EY29W7EC (miltefosine)
- Publication Date:
Date Created: 20190215 Date Completed: 20190320 Latest Revision: 20200225
- Publication Date:
20221213
- Accession Number:
PMC6392311
- Accession Number:
10.1371/journal.pntd.0007133
- Accession Number:
30763330
No Comments.